keyword
MENU ▼
Read by QxMD icon Read
search

"Hepatitis c" budget value

keyword
https://www.readbyqxmd.com/read/27468625/public-participation-in-decision-making-on-the-coverage-of-new-antivirals-for-hepatitis-c
#1
Katharina Kieslich, Jeonghoon Ahn, Gabriele Badano, Kalipso Chalkidou, Leonardo Cubillos, Renata Curi Hauegen, Chris Henshall, Carleigh B Krubiner, Peter Littlejohns, Lanting Lu, Steven D Pearson, Annette Rid, Jennifer A Whitty, James Wilson
Purpose - New hepatitis C medicines such as sofosbuvir underline the need to balance considerations of innovation, clinical evidence, budget impact and equity in health priority-setting. The purpose of this paper is to examine the role of public participation in addressing these considerations. Design/methodology/approach - The paper employs a comparative case study approach. It explores the experience of four countries - Brazil, England, South Korea and the USA - in making coverage decisions about the antiviral sofosbuvir and involving the public and patients in these decision-making processes...
August 15, 2016: Journal of Health Organization and Management
https://www.readbyqxmd.com/read/26667111/-in-process-citation
#2
Béla Hunyady, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Gabriella Lengyel, Alajos Pár, Zoltán Péter, László Rókusz, Ferenc Schneider, Ferenc Szalay, István Tornai, Klára Werling, Mihály Makara
Approximately 70.000 people are infected with hepatitis C virus in Hungary, more than half of whom are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy on one hand. From socioeconomic aspect, this could also prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity...
December 15, 2015: Orvosi Hetilap
https://www.readbyqxmd.com/read/26109044/association-of-serum-vitamin-b12-levels-with-stage-of-liver-fibrosis-and-treatment-outcome-in-patients-with-chronic-hepatitis-c-virus-genotype-1-infection-a-retrospective-study
#3
Nicolae-Catalin Mechie, Armin D Goralzcyk, Lars Reinhardt, Sabine Mihm, Ahmad Amanzada
BACKGROUND: Chronic hepatitis C (CHC) is a global health challenge. New therapeutic agents with excellent sustained virological response (SVR) rates are available mainly in developed countries, while the majority of CHC patients live in countries with low health budget. Predictors of therapeutic response are therefore necessary. Vitamin B12 appears to be involved in hepatitis C virus replication. METHODS: We therefore studied retrospectively the relationship between baseline serum vitamin B12 levels and clinical features in 116 CHC genotype 1 infected patients...
2015: BMC Research Notes
https://www.readbyqxmd.com/read/26085900/breaking-the-bank-three-financing-models-for-addressing-the-drug-innovation-cost-crisis
#4
REVIEW
J D Kleinke, Nancy McGee
BACKGROUND: The introduction of innovative specialty pharmaceuticals with high prices has renewed efforts by public and private healthcare payers to constrain their utilization, increase patient cost-sharing, and compel government intervention on pricing. These efforts, although rational for individual payers, have the potential to undermine the public health impact and overall economic value of these innovations for society. The emerging archetypal example is the outcry over the cost of sofosbuvir, a drug proved to cure hepatitis C infection at a cost of $84,000 per person for a course of treatment (or $1000 per tablet)...
May 2015: American Health & Drug Benefits
https://www.readbyqxmd.com/read/26039413/-in-process-citation
#5
Béla Hunyady, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Gabriella Lengyel, Alajos Pár, László Rókusz, Ferenc Szalay, László Telegdy, István Tornai, Klára Werling, Mihály Makara
Approximately 70,000 people are infected with hepatitis C virus in Hungary, and more than half of them are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy. From a socioeconomic aspect, this could also prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity...
March 2015: Orvosi Hetilap
https://www.readbyqxmd.com/read/25775312/cost-effectiveness-and-budget-impact-of-hepatitis-c-virus-treatment-with-sofosbuvir-and-ledipasvir-in-the-united-states
#6
Jagpreet Chhatwal, Fasiha Kanwal, Mark S Roberts, Michael A Dunn
BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection...
March 17, 2015: Annals of Internal Medicine
https://www.readbyqxmd.com/read/25702254/-hepatitis-c-diagnosis-anti-viral-therapy-after-care-hungarian-consensus-guideline
#7
REVIEW
Béla Hunyady, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Gabriella Lengyel, Alajos Pár, László Rókusz, Ferenc Szalay, László Telegdy, István Tornai, Klára Werling, Mihály Makara
Approximately 70,000 people are infected with hepatitis C virus in Hungary, and more than half of them are not aware of their infection. From the point of infected individuals early recognition and effective treatment of related liver injury may prevent consequent advanced liver diseases and complications (liver cirrhosis, liver failure and liver cancer) and can increase work productivity and life expectancy. Furthermore, these could from prevent further spread of the virus as well as reduce substantially long term financial burden of related morbidity, as a socioeconomic aspect...
March 1, 2015: Orvosi Hetilap
https://www.readbyqxmd.com/read/24379676/cost-analysis-of-initial-highly-active-antiretroviral-therapy-regimens-for-managing-human-immunodeficiency-virus-infected-patients-according-to-clinical-practice-in-a-hospital-setting
#8
Giorgio L Colombo, Antonella Castagna, Sergio Di Matteo, Laura Galli, Giacomo Bruno, Andrea Poli, Stefania Salpietro, Alessia Carbone, Adriano Lazzarin
OBJECTIVE: In the study reported here, single-tablet regimen (STR) versus (vs) multi-tablet regimen (MTR) strategies were evaluated through a cost analysis in a large cohort of patients starting their first highly active antiretroviral therapy (HAART). Adult human immunodeficiency virus (HIV) 1-naïve patients, followed at the San Raffaele Hospital, Milan, Italy, starting their first-line regimen from June 2008 to April 2012 were included in the analysis. METHODS: The most frequently used first-line HAART regimens (>10%) were grouped into two classes: 1) STR of tenofovir disoproxil fumarate (TDF) + emtricitabine (FTC) + efavirenz (EFV) and 2) MTR including TDF + FTC + EFV, TDF + FTC + atazanavir/ritonavir (ATV/r), TDF + FTC + darunavir/ritonavir (DRV/r), and TDF + FTC + lopinavir/ritoavir (LPV/r)...
2014: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/17166063/-budget-impact-analysis-of-the-treatment-of-chronic-hepatitis-c-in-a-hospital
#9
COMPARATIVE STUDY
M A Casado Gómez, L Alvarez-Rubio, S Miró Manero, E L Mariño Hernández, M Buti Ferret
OBJECTIVE: To perform a budget impact analysis (BIA) of the treatment with pegylated interferon (pegIFN), alfa-2a or alfa-2b, plus ribavirin in patients with chronic hepatitis C (CHC). METHOD: An interactive model has been designed from the inputs obtained from hospital databases. Prices for pegIFN and RIB have been taken from the hospitals considering their respective discounts. Only pharmacological costs (euros 2005 values) for the options have been considered...
September 2006: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/16235977/financial-impact-of-two-different-ways-of-evaluating-early-virological-response-to-peginterferon-alpha-2b-plus-ribavirin-therapy-in-treatment-naive-patients-with-chronic-hepatitis-c-virus-genotype-1
#10
REVIEW
Maria Buti, Miguel A Casado, Leslie Fosbrook, Rafael Esteban
BACKGROUND: Patients infected with chronic hepatitis C virus (HCV) genotype 1 are the least responsive to peginterferon (pegIFN) and ribavirin therapy. The monitoring of early virological response (EVR) is therefore an important tool for quickly identifying non-responders, permitting therapy discontinuation and avoiding adverse effects and costs. OBJECTIVE: To analyse the financial impact, in treatment-naive patients infected with HCV genotype 1, of two different measurement techniques for evaluating the EVR during pegIFN-alpha-2b plus ribavirin therapy, and to compare the results of a 48-week standard course of therapy with pegIFN-alpha-2b plus ribavirin without measuring EVR...
2005: PharmacoEconomics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"